drugset / Trial / NCT04433494

A Study of TY-302 in Patients With Advanced Solid Tumors

NCT04433494

Phase 1 Unknown 60 enrolled TYK Medicines, Inc
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: * TY-302 * Tamoxifen

Timeline

Start
2020-12-07
Primary completion
2023-05
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 20 mg Oral
Subject Tamoxifen Small molecule 25 mg Oral
Subject Tamoxifen Small molecule 50 mg Oral

Indications